IP Verse

Therapeutic - EP3132034

The patent EP3132034 was granted to Nemesis Bioscience on Aug 19, 2020. The application was originally filed on Apr 14, 2015 under application number EP15718982A. The patent is currently recorded with a legal status of "Revoked".

EP3132034

NEMESIS BIOSCIENCE
Application Number
EP15718982A
Filing Date
Apr 14, 2015
Status
Revoked
Mar 1, 2024
Grant Date
Aug 19, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ELIGO BIOSCIENCEMay 18, 2021JANADMISSIBLE

Patent Citations (2) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTWO2010075424
OPPOSITIONWO2014124226

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- Huang, "E. curi: A way of deactivating antibiotic resistance genes in E. coli", (20120401), URL: http://uscusj.weebly.com/uploads/4/9/5/1/4951238/jonathan__usj__v3.pdf, (20150803), XP002742963 [X] 1 * the whole document * [I] 2-26-
INTERNATIONAL-SEARCH-REPORT- CITORIK ROBERT J ET AL, "Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases", NATURE BIOTECHNOLOGY, (20141101), vol. 32, no. 11, pages 1141 - 1145+2PP, XP002742964 [XP] 1-26 * the whole document *
INTERNATIONAL-SEARCH-REPORT- BIKARD DAVID ET AL, "Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials", NATURE BIOTECHNOLOGY, (201411), vol. 32, no. 11, pages 1146 - 1150, XP002742966 [XP] 1-26 * the whole document *
INTERNATIONAL-SEARCH-REPORT- YOSEF IDO ET AL, "Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (20150609), vol. 112, no. 23, ISSN 1091-6490, pages 7267 - 7272, XP002742965 [T] * the whole document *
OPPOSITION- Anonymous, "ATCC Product Sheet Escherichia coli (ATCC® 47055™)", American Type Culture Collection, pages 1 - 2-
OPPOSITION- ANONYMOUS, "Safety Data Sheet LB BROTH 10855001", Thermo Fisher Scientific, (20200413), pages 1 - 9, XP055825923-
OPPOSITION- Laura A. Dever, Terence S, Dermody, "Mechanisms of Bacterial Resistance to Antibiotics", Arch Intern Med, (19910500), vol. 151, pages 886 - 895, XP055826016-
OPPOSITION- Shengdar Q Tsai; Nicolas Wyvekens; Cyd Khayter; Jennifer A Foden; Vishal Thapar; Deepak Reyon; Mathew J Goodwin; Martin J Aryee; Keith Joung J, "Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing /HHS Author Manuscript/", Nat. Biotechnol., (20140425), vol. 32, pages 569 - 576, XP055826007-
OPPOSITION- Citorik Robert J, Mimee Mark, Lu Timothy K, "Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases /NIH Author Manuscript/", Nat. Biotechnol., (20140921), vol. 32, pages 1 - 18, XP055825907
OPPOSITION- Robert J Citorik; Mimee Mark; Lu Timothy K, "Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases Supplementary Material", Nature Biotechnology, (20140921), pages 1 - 14, XP055345843
OPPOSITION- Bikard David, Euler Chad, Jiang Wenyan, Nussenzweig Philip M, Goldberg Gregory W, Duportet Xavier, Fischetti Vincent A, Marraffini Luciano A, "Development of sequence-specific antimicrobials based onprogrammable CRISPR-Cas nucleases /HHS Author Manuscript/", Nat. Biotechnol., (20141005), vol. 32, pages 1146 - 1150, XP055826004
OPPOSITION- Ami M. Kabadi, David G. Ousterout, Isaac B. Hilton and Charles A. Gersbach, "Multiplex CRISPR/Cas9-based genome engineeringfrom a single lentiviral vector", Nucleic Acids Res., (20140813), vol. 42, no. 19, page e147, XP055177310
OPPOSITION- Brian Chaikind, Jeffrey L. Bessen, David B. Thompson, Johnny H. Hu and David R. Liu, "A programmable Cas9-serine recombinase fusionprotein that operates on DNA sequences in mammalian cells", Nucleic Acids Research, (2016), vol. 44, no. 20, pages 9758 - 9770, XP055411362
OPPOSITION- PETER KUHNERT, JACQUES NICOLET, and JOACHIM FREY, "Rapid and Accurate Identification of Escherichia coli K-12 Strains", Applied and Environmental Microbiology, (199511), vol. 61, no. 11, pages 4135 - 4139, XP055825940
OPPOSITION- Chris Proudfoot, Arlene L. McPherson, Andreas F. Kolb, W. Marshall Stark, "Zinc Finger Recombinases with Adaptable DNA Sequence Specificity", PLoS ONE, (20110429), vol. 6, page e19537, XP055826011

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents